Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-11-18
2000-07-25
Chan, Christina Y.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 21, 4241851, 4242781, 530351, A61K 3818, C07K 14475
Patent
active
060936932
ABSTRACT:
A novel protein purified from bovine colostral whey and isolated nucleotide sequences encoding the protein. The isolated bovine protein has homology with human CD14 and murine CD14 and so is referred to as bovine CD14. A method of activating B cells, and particularly of activating B cells in a mammal, such as a human, in need of such activation by administering CD14 is described. CD14 can be incorporated into infant formula. CD14 can be administered to an infant, as by feeding to the infant such formula. CD14 can be incorporated as part of a vaccination. CD14 can be administered to a patient having a T cell immune deficiency, for example, a particular T cell dysfunction in which gp39 is under expressed on or totally absent from the cell surface of patient T cells. Preparation of medicaments including CD14 for activating B cells in a mammal in need of such activation is described. Natural or recombinant CD14 can be used.
REFERENCES:
patent: 5543303 (1996-08-01), Goyert
Loms, Ziegler-Heitbrock, H.W. et al., European Journal of Immunology, 24(8):1937-1940 1994, "CD14 is expressed and functional in human B cells."
Ulevitch, R.J. et al., Annual Review of Immunology, 13:437-457, 1995, "Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. "
Yang et al. "Analysis of the CD14 receptor associated with bovine alveolar macrophages", Inflammation, 20(1):97-106, XP002062355, Feb. 1996.
Setoguchi et al., "Mouse and human CD14 (myeloid cell-specific leucin rich glycoprotein) primary structure deduced from cDNA clones", Biochimica et Biophysica ACTA, 1008(2):213-222, XP002062356 (1989).
Jabara et al. "Engagement of CD14 on monocytes inhibits the synthesis of human Igs., including IgE", The Journal of Immunology, 153:972-978, XP002062357 (1994).
Ikeda et al., "Molecular cloning of bovine CD14 gene", J. Vet. Med. Sci., 59(8):715-719, XP002062359 (1997).
Wang, et al., "Detection and identification of soluble CD14 in bovine milk", Molecular Biology of the Cell, 8(5):85a, XP002062360, Nov. 1997.
Yang et al., "Soluble CD14 lipopolysaccharide-binding protein from bovine serum enable bacterial lipopolysaccharide-mediated cytotoxicity and activation of . . . ", Journal of Leukocyte Biology, 59(2):241-247, XP002062361, Feb. 1996.
Simmons et al., "Monocyte antigen CD14 is a phospholipid anchored membrane protein" Blood, 73(1):284-289, XP002062358, Jan. 1989.
Juan, Todd S.-C, et al., The Journal of Biological Chemistry, 270:1382-1387, 1995, "Soluble CD14 truncated at amino acid 152 binds lipopolysaccharide (LPS) and enables cellular responses to LPS".
Viriyakosal, S. and T.H. Kirkland, Infection and Immunity 64:653-656, 1996. "The N-terminal half of membrane CD14 is a functional cellular lipopolysaccharide receptor".
"A Colostral Protein that Induces the Growth and Differentiation of Resting B Lymphocytes". M.H. Julius et al., The Journal of Immunology, vol. 140, pp. 1366-1371, No. 5, Mar. 1, 1987.
Alizadeh-Khiavi Kamel
Filipp Dominik
Julius Michael H.
Chan Christina Y.
Hunt John C.
The Wellesley Hospital Foundation
Tung Mary Beth
LandOfFree
B cell activation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with B cell activation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and B cell activation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1336645